Novartis, Amgen settle their dueling lawsuits over migraine drug Aimovig

Novartis and Amgen have spent years arm wrestling one another over their development and commercialization deal on migraine prevention drug Aimovig. Now, the parties appear ready to drop their dispute and move on.

In a SEC filing Monday, Amgen said the parties were updating the terms of their Aimovig collaboration and settling their dueling lawsuits related to the deal.